Trials / Recruiting
RecruitingNCT05751850
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate Versus Nab-paclitaxel in Combination With Gemcitabine for First-line Treatment of Advanced Pancreatic Cancer: an Open, Randomized, Multicenter Phase III Trial.
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 778 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate | HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate |
| DRUG | nab-paclitaxel; gemcitabine | nab-paclitaxel in combination with gemcitabine |
Timeline
- Start date
- 2023-06-13
- Primary completion
- 2024-12-30
- Completion
- 2025-12-30
- First posted
- 2023-03-02
- Last updated
- 2024-05-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05751850. Inclusion in this directory is not an endorsement.